Antibody and Protein Patent Claims in Biotechnology

Antibodies and proteins are among the most important classes of inventions in biotechnology. They include therapeutic antibodies, engineered enzymes, receptor proteins, fusion proteins, diagnostic reagents, and research tools. They are also difficult patent subjects because their commercial value often lies not only in one molecule, but in a class of related molecules that perform a useful biological function.

As a practical matter, current U.S. law tends to push antibody claims away from simple antigen-based definitions and toward claims supported by antibody structure, binding-site information, epitope data, and demonstrated biological activity. This does not mean that every valid antibody claim must include a complete structural map of the antibody-antigen interaction. But it does mean that an application is usually stronger when it identifies actual antibodies and explains why those antibodies support the claim scope being sought.

At the narrow end, an antibody or protein can be claimed by its amino acid sequence. For example, a claim may be directed to an antibody having defined heavy-chain and light-chain sequences, or to a protein having a particular sequence and specified activity. These claims are usually the most straightforward because the application identifies the actual molecule being claimed. They may also be valuable if the molecule itself corresponds to the commercial product.

The problem is that narrow sequence claims may leave room for competitors. A competitor may attempt to develop a different antibody or protein variant that performs essentially the same commercial function but differs enough in sequence to avoid literal infringement. This reflects the same tension discussed in earlier Snapshots: the desire to claim broadly based on a limited number of disclosed examples. For this reason, applicants often seek broader claims. They may want protection for antibodies that bind the same target, recognize the same epitope, block the same receptor interaction, or neutralize the same biological pathway. Similarly, they may want claims covering protein variants that retain a desired enzymatic, binding, signaling, or therapeutic activity.

This is where antibody and protein claims become challenging. For antibodies, the antigen is the larger target molecule, while the epitope is the particular part of the antigen recognized by the antibody. Two antibodies may bind the same antigen but bind different epitopes and have very different effects. One antibody may simply attach to the target, while another may block receptor binding, neutralize a virus, inhibit signaling, recruit immune effector cells, or deliver a drug payload. Much of this activity depends on the antibody’s binding region, including the complementarity-determining regions (CDRs), which form much of the binding surface.

Proteins present a similar problem. A protein may tolerate some amino acid substitutions without losing activity, while other changes may disrupt folding, stability, binding, catalytic activity, or expression. Even when variants can be generated and screened using known methods, that does not necessarily mean that the applicant can claim every variant that later proves to work.

The practical drafting issue is therefore one of scope. A claim to one disclosed sequence may be too narrow for business purposes, while a claim to all antibodies or proteins having a desired function may be too broad unless the application contains sufficient structural and functional information to support that breadth. The strongest applications usually provide multiple layers of disclosure: complete sequences, CDRs or active regions, binding data, activity assays, specificity information, variant data, and, where possible, epitope or structure-function information.

Good claim strategy often follows the same layered approach. Narrow claims may cover the exact antibody or protein sequence. Intermediate claims may cover defined CDRs, fragments, conservative variants, sequence-identity ranges, or molecules retaining specified activity. Broader claims may be possible when the disclosure supports a meaningful class rather than merely identifying a desired result. Additional protection may come from method-of-treatment claims, diagnostic claims, antibody-drug conjugate claims, formulations, combinations, dosing regimens, or manufacturing methods.

For biotechnology companies and investors, the important question is not simply whether an antibody or protein patent exists. The question is whether the claims capture commercially meaningful alternatives while remaining tied to what the application actually teaches. A patent can be too narrow to matter or too broad to survive. The strongest position usually lies between those extremes: claims that are broad enough to protect the commercial opportunity, but grounded in sufficient technical disclosure to show that the inventor made and understood the invention being claimed.

Disclaimer: This piece is provided for general informational purposes only and does not constitute legal advice. Patent issues are often complex and highly fact-specific, and no one should act on general information of this kind without consulting qualified patent counsel regarding the particular circumstances involved.